BIOGEN INC (BIIB)
US09062X1037 - Common Stock
BIIB June 7th Options Begin Trading
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser.
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA® ...
Why Biogen Stock Leaped Nearly 5% Higher Today
The company came out swinging with its first set of quarterly earnings for this year.
Notable Wednesday Option Activity: BIIB, ABNB, HPQ
In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Wednesday's session.
Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below.
Biogen (BIIB) Q1 2024 Earnings Call Transcript
BIIB earnings call for the period ending March 31, 2024.
Which S&P500 stocks are moving on Wednesday?
Wednesday's session: top gainers and losers in the S&P500 index
BIIB Stock Earnings: Biogen Beats EPS, Misses Revenue for Q1 2024
BIIB stock results show that Biogen beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
These S&P500 stocks are moving in today's pre-market session
Curious about the S&P500 stocks that are showing activity before the opening bell on Wednesday?
Biogen Q1 2024 results surpass expectation despite revenue decline
Biogen Inc. (NASDAQ: BIIB), a leading biotechnology company, has released its Q1 2024 financial results, showcasing resilience and strategic growth despite facing revenue challenges. In the first quarter of 2024, Biogen reported a revenue of $2.29 billion, which slightly missed expectations by $30 million. However, the company demonstrated a meaningful improvement in both gross and […]
Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline?
Biogen shares have lost nearly 40% of their value since last June. Could two key sales beats help revive shares?
Biogen Profit Beats Street Estimates as Cost-Cutting Takes Hold
Biogen Inc. reported first-quarter profit that beat Wall Street’s expectations, as the biotech giant cut costs and its new Alzheimer’s drug Leqembi gained momentum.
Nasdaq 100 Movers: AMD, FANG
BIIB May 31st Options Begin Trading
Biogen Enters Oversold Territory (BIIB)
BIIB May 24th Options Begin Trading
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom.
BIIB May 3rd Options Begin Trading
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
First Week of May 17th Options Trading For Biogen (BIIB)
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BIIB
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are...